Investigational drug · Phase 3
Cebranopadol
Also called: TRN-228
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pain, Acute Pain, Chronic Pain.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
2 still active
All registered trials
14
Any phase or sponsor naming "Cebranopadol"
First trial start
2024
Jul 18, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Cebranopadol", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pain
- Acute Pain
- Chronic Pain
- Opioid Withdrawal (Disorder)
- Opioid Use Disorder
Approved drugs for the same conditions: Opioid use disorder · Acute pain · Psychiatry · Pain and anesthesia
Largest trials
Live from ClinicalTrials.gov: studies naming "Cebranopadol" as an intervention, largest first.
- Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the NervesPivotal-lookingCompleted
Tris Pharma, Inc.Industry
NCT01939366 · 699 participants · Start Sep 27, 2013 · Primary completion Jan 2015
Drug: Cebranopadol 100 µg; Cebranopadol 300 µg and 3 more · For: Chronic Pain; Diabetic Neuropathies; Diabetes Mellitus
Sites: Mesa, Arizona; Garden Grove, California; Laguna Hills, California · 82 sites in all
- Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee PainPivotal-lookingCompleted
Tris Pharma, Inc.Industry
NCT01709214 · 619 participants · Start Dec 4, 2012 · Primary completion Apr 2014
Drug: Cebranopadol (GRT6005) Low-Dose Range; Cebranopadol (GRT6005) High-Dose Range and 2 more · For: Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
Sites: Birmingham, Alabama; Huntsville, Alabama; Phoenix, Arizona · 83 sites in all
- A Study of Cebranopadol for the Treatment of Acute Pain After AbdominoplastyPivotal-lookingCompleted
Tris Pharma, Inc.Industry
NCT06545097 · 279 participants · Start Sep 3, 2024 · Primary completion Dec 30, 2024
Drug: Cebranopadol 400 ug; Cebranopadol 200 ug and 1 more · For: Acute Pain
Sites: Little Rock, Arkansas; Miami, Florida; Bellaire, Texas · 4 sites in all
- A Study of Cebranopadol for the Treatment of Acute Pain After BunionectomyPivotal-lookingCompleted
Tris Pharma, Inc.Industry
NCT06423703 · 240 participants · Start Jul 18, 2024 · Primary completion Jan 31, 2025
Drug: Cebranopadol; Oxycodone IR and 2 more · For: Acute Pain
Sites: Sheffield, Alabama; Little Rock, Arkansas; Tampa, Florida · 10 sites in all
- A Trial to Evaluate the Abuse Potential of 3 Doses of GRT6005 in Adult Non-dependent Recreational Opioid UsersPivotal-lookingCompleted
Tris Pharma, Inc.Industry
NCT03757559 · 226 participants · Start Apr 15, 2013 · Primary completion Mar 8, 2014
Drug: Cebranopadol 100 micrograms; Cebranopadol 400 micrograms and 3 more · For: Abuse, Drug
Sites: Toronto, Canada
- CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to CancerPivotal-lookingTerminated
Tris Pharma, Inc.Industry
NCT01964378 · 200 participants · Start Oct 29, 2013 · Primary completion Oct 16, 2015
Drug: Cebranopadol; Morphine Prolonged Release · For: Pain; Neoplasms; Chronic Pain
Sites: Vienna, Austria; Brussels, Belgium; Ottignies, Belgium · 42 sites in all
- Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Heart in Healthy SubjectsPivotal-lookingCompleted
Tris Pharma, Inc.Industry
NCT03958123 · 171 participants · Start Jul 10, 2013 · Primary completion Nov 27, 2013
Drug: 100 μg cebranopadol; 200 μg cebranopadol and 4 more · For: Prolonged QTc Interval; Pharmacokinetic
Sites: West Bend, Wisconsin
- An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical OriginPivotal-lookingRecruiting
Adneuris Therapeutics, Inc.Industry
NCT07845071 · 160 participants (planned) · Start Sep 22, 2026 · Primary completion Jan 2027
Drug: Cebranopadol 400 ug · For: Pain
Sites: Phoenix, Arizona; Riverside, California; Longmont, Colorado · 15 sites in all
- CORAL XT - Open-label Extension Trial of the CORAL TrialPivotal-lookingCompleted
Tris Pharma, Inc.Industry
NCT02031432 · 76 participants · Start Dec 18, 2013 · Primary completion Apr 2016
Drug: Cebranopadol · For: Pain; Neoplasms; Chronic Pain
Sites: Vienna, Austria; Sint-Niklaas, Belgium; Shumen, Bulgaria · 22 sites in all
Tris Pharma, Inc.Industry
NCT06453265 · 48 participants · Start Jun 28, 2024 · Primary completion Nov 6, 2024
Drug: Cebranopadol- 600 ug; Cebranopadol- 800ug and 6 more · For: Abuse, Drug
Sites: Columbus, Ohio
Newest research
PubMed records naming it or its code names, newest first.
- Nociceptin/Orphanin FQ Peptide (NOP) Receptor Agonists as Novel Analgesics in Pain Medicine.
Shehata IM, Ahmed Kamal M, Makki TM, et al. · J Clin Med 2026
- Structural basis for dual targeting of μ-opioid and nociceptin/orphanin FQ receptors by Cebranopadol.
Lai YL, Huang XY, Shen SY, et al. · Acta Pharmacol Sin 2026
- Emerging technologies in acute pain management.
Ramanujam V, Warzecha H, Shah Y, et al. · Pain Manag 2026
- Respiratory and Antinociceptive Effects of Nociceptin Receptor-µ-Opioid Receptor Agonist Cebranopadol versus Full Opioid Receptor Agonist Oxycodone: A Comparison in Healthy Volunteers.
Jansen S, Olofsen E, Moss L, et al. · Anesthesiology 2026
- Narcotics through time: exploring historical origins, synthetic advances, and clinical progress.
Kalita RC, Sharma S, Samanta S, et al. · Future Med Chem 2025
- Drugs in Development to Manage Acute Pain.
Oliver B, Devitt C, Park G, et al. · Drugs 2025
Also in development for Pain
- Active Comparator: MorphinePhase 32 trials
Shanghai Haiyan Pharmaceutical Technology Co., Ltd. · Pain
- CT001Phase 31 trial
Cessatech A/S · Pain
- MR-107A-02Phase 31 trial
Viatris Specialty LLC · Acute Pain, Post Operative Pain, Pain
- SRP-001Phase 21 trial
South Rampart Pharma, Inc. · Acute Pain, Postoperative Pain, Pain
- YZJ-4729Phase 21 trial
Shanghai Haiyan Pharmaceutical Technology Co., Ltd. · Pain
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.